Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays
Authors:
- Ariane HallermayrAHAriane Hallermayr
- Thomas KeßlerTKThomas Keßler
- Moritz FujeraMFMoritz Fujera
- Ben LiesfeldBLBen Liesfeld
- Samuel BernsteinSBSamuel Bernstein
- Simon von AmelnSASimon von Ameln
- Denny SchanzeDSDenny Schanze
- Verena Steinke-LangeVSVerena Steinke-Lange
- Julia M. A. PicklJPJulia M. A. Pickl
- Teresa M. NeuhannTNTeresa M. Neuhann
- Elke Holinski-FederEHElke Holinski-Feder
Open Access
Abstract
Background: Liquid biopsy enables the non-invasive analysis of genetic tumor variants in circulating free DNA (cfDNA) in plasma. Accurate analytical validation of liquid biopsy NGS assays is required to detect variants with low variant allele frequencies (VAFs). Methods: Six types of commercial cfDNA reference materials and 42 patient samples were analyzed using a duplex-sequencing-based liquid biopsy NGS assay. Results: We comprehensively evaluated the similarity of commercial cfDNA reference materials to native cfDNA. We observed significant differences between the reference materials in terms of wet-lab and sequencing quality as well as background noise. No reference material resembled native cfDNA in all performance metrics investigated. Based on our results, we established guidelines for the selection of appropriate reference materials for the different steps in performance evaluation. The use of inappropriate materials and cutoffs could eventually lead to a lower sensitivity for variant detection. Conclusion: Careful consideration of commercial reference materials is required for performance evaluation of liquid biopsy NGS assays. While the similarity to native cfDNA aids in the development of experimental protocols, reference materials with well-defined variants are preferable for determining sensitivity and precision, which are essential for accurate clinical interpretation.Keywords
This publication has 24 references indexed in Scilit:
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studiesInternational Journal of Cancer, 2020
- Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working GroupClinical Chemistry, 2020
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trialVirchows Archiv, 2017
- Detection of ultra-rare mutations by next-generation sequencingProceedings of the National Academy of Sciences, 2012
- Analysis of Circulating Tumor DNA to Confirm Somatic KRAS MutationsJNCI: Journal of the National Cancer Institute, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Detection and quantification of mutations in the plasma of patients with colorectal tumorsProceedings of the National Academy of Sciences, 2005